SCHEMBL13310045

SCHEMBL13310045

CCOC(=O)CNC(=O)Cc1ccc(Cl)cc1Nc1ncnc2cc(OC)c(O)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.51
HDAC3 O15379 9/20 0.49
HDAC4 P56524 9/20 0.49
HDAC1 Q13547 9/20 0.49
HDAC7 Q8WUI4 9/20 0.49
HDAC2 Q92769 9/20 0.49
HDAC10 Q969S8 9/20 0.49
HDAC11 Q96DB2 9/20 0.49
HDAC8 Q9BY41 9/20 0.49
HDAC6 Q9UBN7 9/20 0.49
HDAC9 Q9UKV0 9/20 0.49
HDAC5 Q9UQL6 9/20 0.49
EGFR P00533 5/20 0.49
SRC P12931 1/20 0.47
RAF1 P04049 1/20 0.46
BRAF P15056 1/20 0.46
FGFR1 P11362 1/20 0.46
FLT1 P17948 1/20 0.46
EPHB2 P29323 1/20 0.46
FLT4 P35916 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13310060 0.90 KDR (0.51) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL13310046 0.88 KDR (0.56) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL20752924 0.82 KDR (0.49) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL20752912 0.82 KDR (0.49) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL20752925 0.82 KDR (0.49) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL535218 0.81 KDR (0.53) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL13310048 0.80 EGFR (0.58) KDREGFRSRCBRAFFGFR1
SCHEMBL535303 0.78 EGFR (0.59) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL535118 0.78 EGFR (0.49) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL535365 0.77 EGFR (0.50) KDRHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208062-B2 Macrocyclic quinazole derivatives and their use as MTKI JANSSEN PHARMACEUTICA NV (BE) 2019-02-19 US disclosed
US-20170320894-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 US disclosed
US-9688691-B2 Macrocyclic quinazole derivatives and their use as MTKI JANSSEN PHARMACEUTICA NV (BE) 2017-06-27 US disclosed
US-20140256714-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 US disclosed
US-20100152174-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN-CILAG (FR) 2010-06-17 US disclosed
US-20100152174-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN-CILAG (FR) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256714-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR3C2, NR1I2 KDR 2610/4885HDAC3 193/4885HDAC4 1205/4885
US-20100152174-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR1I2, NR3C2 KDR 2757/4885HDAC3 143/4885HDAC4 974/4885
US-20170320894-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR3C2, NR1I2 KDR 2610/4885HDAC3 193/4885HDAC4 1205/4885
US-10208062-B2 Macrocyclic quinazole derivatives and their use as MTKI NR1I3, NR3C2, NR1I2 KDR 2610/4885HDAC3 193/4885HDAC4 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.